Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled AsthmaBusiness Wire • 01/04/22
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus NephritisBusiness Wire • 01/04/22
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with ItolizumabBusiness Wire • 12/13/21
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development UpdatesBusiness Wire • 11/10/21
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology MeetingBusiness Wire • 11/05/21
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual MeetingBusiness Wire • 11/05/21
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and ExpositionBusiness Wire • 11/04/21
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual MeetingBusiness Wire • 11/02/21
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual MeetingBusiness Wire • 10/18/21
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021Business Wire • 09/30/21
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare ConferenceBusiness Wire • 09/22/21
Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/08/21
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus NephritisBusiness Wire • 08/11/21
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development UpdateBusiness Wire • 08/10/21
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDAGlobeNewsWire • 07/12/21
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential24/7 Wall Street • 06/19/21
Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease PatientsBenzinga • 06/11/21
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host DiseaseGlobeNewsWire • 06/11/21
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of CytometryGlobeNewsWire • 06/10/21
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic DiseasesGlobeNewsWire • 06/07/21